Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 3/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787150 | 0.90 | ACHE (0.33) | ACHEMCHR1BCHECCR5SLC2A1 | |
| SCHEMBL380566 | 0.86 | CHRM2 (0.46) | SLC2A1CHRM2 | |
| SCHEMBL768154 | 0.85 | TRPV4 (0.33) | SLC2A1CHRM2 | |
| SCHEMBL768753 | 0.81 | MCHR1 (0.42) | ACHEMCHR1CCR5CHRM2MEN1 | |
| SCHEMBL768562 | 0.79 | MCHR1 (0.41) | ACHEMCHR1CCR5SLC2A1CHRM2 | |
| SCHEMBL768575 | 0.79 | BCHE (0.38) | ACHEMCHR1BCHECHRM2OPRM1 | |
| SCHEMBL769174 | 0.79 | MCHR1 (0.41) | ACHEMCHR1CCR5CHRM2MEN1 | |
| SCHEMBL768119 | 0.78 | MCHR1 (0.35) | ACHEMCHR1BCHECHRM2 | |
| SCHEMBL769446 | 0.78 | OPRM1 (0.33) | MCHR1CCR5SLC2A1CHRM2OPRM1 | |
| SCHEMBL768307 | 0.78 | MCHR1 (0.42) | ACHEMCHR1CCR5CHRM2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | ACHE 687/4885MCHR1 239/4885BCHE 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.